Un viaje por las propuestas de la ciencia ficción sobre medicina personalizada, y cómo las hemos ido cumpliendo, sobre todo gracias a las nuevas tecnologías de secuenciación en las I Jornadas Ciencia y Salud organizadas por el Ateneo Mijas.
De los rasgos poligénicos a los poligenómicos 250517M. Gonzalo Claros
The document discusses DNA storage as a potential solution for handling the growing amount of digital data being generated. It describes how researchers were able to store a computer operating system and short movie in DNA using an encoding strategy called "DNA Fountain" that maximizes the data storage capacity of DNA molecules. The encoding approach involved compressing files into segments, transforming the segments into DNA "droplets" using a random selection process and error correcting codes, and screening droplets to identify valid DNA sequences to store the data. The researchers demonstrated storing over 2 megabytes of data in a DNA library with 100% accurate recovery of information after sequencing.
0 A Work Project, presented as part of the requireme.docxoswald1horne84988
0
A Work Project, presented as part of the requirements for the Award of a Masters
Degree in Management from the Nova School of Business and Economics
Illumina:
The sustainability of its competitive position
Marta Gonçalves Serra #1467
A project carried out on the Strategy course, under the supervision of
Professor Luís Almeida Costa
December 2014
1
Acknowledgements
I would like to sincerely thank my supervisor, Professor Luís Almeida Costa, for his
patient guidance, availability and advice he has given me throughout the course of this
project. His mentorship was essential for the success of this work and ultimately, for my
overall and round learning. I would also like to thank Stathis Kanterakis, member of the
Bioinformatics team at Illumina (Cambridge, United Kingdom) for all the information he
shared with me regarding Illumina and the Sequencing Market. He also made possible the
opportunity to visit Illumina’s site at Cambridge and to directly meet employees. All his
contributions were essential to get a greater insight of the company. Additionally, I would
also like to thank my sister, Eva Serra, currently a PhD student at Cambridge and the
Wellcome Trust Sanger Institute, for her continued support in terms of scientific and
technical understanding of the human genome area.
2
Introduction
This work project presents a case study about the sustainability of the competitive position of
Illumina in the Sequencing Market. This is a very recent market, which is growing at
unexpected rates and is contributing for many scientific discoveries. Illumina is currently the
market leader in the sequencing devices manufacturing business and aims to become the
leading company from manufacturing to end-users. Traditionally, Illumina manufactures
instruments and pass them to the next intermediaries, which are service providers. However,
more recently Illumina has not only been manufacturing devices but also developing and
selling solutions directly to consumers. In such a dynamic and fast-growing market,
predicting the future of the industry is particularly difficult. Furthermore, firms face important
challenges when trying to sustain (and enhance) their competitive position. This is precisely
the challenge that Illumina is facing. Since the objective was to conduct and in depth analyze
the competitive situation of a company – Illumina –, the elaboration of a case study seemed to
be the most appropriate approach.
The work project is composed by a case study and a case discussion. The case study starts
with an overview of the Sequencing Market. We then describe Illumina’s positioning in terms
of market segments and products offered. After that, we present some facts about Illumina’s
performance. Finally, we leave some questions for discussion. The case discussion will focus
on the value creation potential of Illumina and the sustainability .
The SMART-NANO project has enabled the development of an innovative and cost-effective technology platform that provides a complete "sample-to-result" solution for the detection, identification and measurement of nanoparticles designed in a wide range of matrices.
This document contains the schedule and program details for the PHARMAPROCESS 2013 conference taking place from October 29-30, 2013. The schedule includes over 30 presentations on topics related to biopharmaceutical development, manufacturing, and regulation. Presentations will cover areas such as novel excipients, cellular therapies, personalized medicine, biosimilars, nanotechnology in drug delivery, biocatalysis, and ensuring global supply of medicines. Keynote speeches will address demand planning, modular facility design, and strategies for combating falsified medicines.
Sources of Innovative Opportunity and Mass-Customization – An Analysis of ...Mikko Ahonen
A short 15-minutes presentation in the 5th World Conference on Mass Customization & Personalization MCPC2009 in Helsinki, Finland.
The actual research paper can be found at: http://beyondcreativity.blogs.com/mblog/2009/09/masscustomization-mcpc2009-emf-health-business-in-drucker-framework.html
This comics book was developped by the Labonfoil projet, a research project funded by the European Commission. I am not the author, just uploaded so that people can view this magnificent piece of science dissemination.
This document describes a proposed technology that would allow users to search the internet based on their genetic profile in order to quickly find cures for diseases. It details how a user's genome could be used to encode a personal medical and financial library by combining various internet and virtual laboratory technologies. Specifically, it posits that this could help develop tailored treatments for cancer by first diagnosing the genetic profile of tumor cells and then using blood-clotting technologies globally to activate pathogens only within tumors, cutting off their blood supply and killing the tumors while leaving healthy cells unaffected.
The document discusses recombinant DNA technology and the Human Genome Project. Some key points:
- The Human Genome Project, started in 1990 and completed in 2003, mapped the entire human genome sequence to further understand human genetics and hereditary disease.
- Recombinant DNA technology allows DNA from one organism to be cut and combined with DNA from another, and is used to produce medicines like human insulin in bacteria.
- Understanding an individual's genetic makeup through projects like the Human Genome Project could help develop personalized medicines tailored to each person's genetics.
- Nutrigenomics studies how different foods may affect gene expression and disease risk depending on a person's genetics. Understanding these interactions could help prevent chronic diseases.
De los rasgos poligénicos a los poligenómicos 250517M. Gonzalo Claros
The document discusses DNA storage as a potential solution for handling the growing amount of digital data being generated. It describes how researchers were able to store a computer operating system and short movie in DNA using an encoding strategy called "DNA Fountain" that maximizes the data storage capacity of DNA molecules. The encoding approach involved compressing files into segments, transforming the segments into DNA "droplets" using a random selection process and error correcting codes, and screening droplets to identify valid DNA sequences to store the data. The researchers demonstrated storing over 2 megabytes of data in a DNA library with 100% accurate recovery of information after sequencing.
0 A Work Project, presented as part of the requireme.docxoswald1horne84988
0
A Work Project, presented as part of the requirements for the Award of a Masters
Degree in Management from the Nova School of Business and Economics
Illumina:
The sustainability of its competitive position
Marta Gonçalves Serra #1467
A project carried out on the Strategy course, under the supervision of
Professor Luís Almeida Costa
December 2014
1
Acknowledgements
I would like to sincerely thank my supervisor, Professor Luís Almeida Costa, for his
patient guidance, availability and advice he has given me throughout the course of this
project. His mentorship was essential for the success of this work and ultimately, for my
overall and round learning. I would also like to thank Stathis Kanterakis, member of the
Bioinformatics team at Illumina (Cambridge, United Kingdom) for all the information he
shared with me regarding Illumina and the Sequencing Market. He also made possible the
opportunity to visit Illumina’s site at Cambridge and to directly meet employees. All his
contributions were essential to get a greater insight of the company. Additionally, I would
also like to thank my sister, Eva Serra, currently a PhD student at Cambridge and the
Wellcome Trust Sanger Institute, for her continued support in terms of scientific and
technical understanding of the human genome area.
2
Introduction
This work project presents a case study about the sustainability of the competitive position of
Illumina in the Sequencing Market. This is a very recent market, which is growing at
unexpected rates and is contributing for many scientific discoveries. Illumina is currently the
market leader in the sequencing devices manufacturing business and aims to become the
leading company from manufacturing to end-users. Traditionally, Illumina manufactures
instruments and pass them to the next intermediaries, which are service providers. However,
more recently Illumina has not only been manufacturing devices but also developing and
selling solutions directly to consumers. In such a dynamic and fast-growing market,
predicting the future of the industry is particularly difficult. Furthermore, firms face important
challenges when trying to sustain (and enhance) their competitive position. This is precisely
the challenge that Illumina is facing. Since the objective was to conduct and in depth analyze
the competitive situation of a company – Illumina –, the elaboration of a case study seemed to
be the most appropriate approach.
The work project is composed by a case study and a case discussion. The case study starts
with an overview of the Sequencing Market. We then describe Illumina’s positioning in terms
of market segments and products offered. After that, we present some facts about Illumina’s
performance. Finally, we leave some questions for discussion. The case discussion will focus
on the value creation potential of Illumina and the sustainability .
The SMART-NANO project has enabled the development of an innovative and cost-effective technology platform that provides a complete "sample-to-result" solution for the detection, identification and measurement of nanoparticles designed in a wide range of matrices.
This document contains the schedule and program details for the PHARMAPROCESS 2013 conference taking place from October 29-30, 2013. The schedule includes over 30 presentations on topics related to biopharmaceutical development, manufacturing, and regulation. Presentations will cover areas such as novel excipients, cellular therapies, personalized medicine, biosimilars, nanotechnology in drug delivery, biocatalysis, and ensuring global supply of medicines. Keynote speeches will address demand planning, modular facility design, and strategies for combating falsified medicines.
Sources of Innovative Opportunity and Mass-Customization – An Analysis of ...Mikko Ahonen
A short 15-minutes presentation in the 5th World Conference on Mass Customization & Personalization MCPC2009 in Helsinki, Finland.
The actual research paper can be found at: http://beyondcreativity.blogs.com/mblog/2009/09/masscustomization-mcpc2009-emf-health-business-in-drucker-framework.html
This comics book was developped by the Labonfoil projet, a research project funded by the European Commission. I am not the author, just uploaded so that people can view this magnificent piece of science dissemination.
This document describes a proposed technology that would allow users to search the internet based on their genetic profile in order to quickly find cures for diseases. It details how a user's genome could be used to encode a personal medical and financial library by combining various internet and virtual laboratory technologies. Specifically, it posits that this could help develop tailored treatments for cancer by first diagnosing the genetic profile of tumor cells and then using blood-clotting technologies globally to activate pathogens only within tumors, cutting off their blood supply and killing the tumors while leaving healthy cells unaffected.
The document discusses recombinant DNA technology and the Human Genome Project. Some key points:
- The Human Genome Project, started in 1990 and completed in 2003, mapped the entire human genome sequence to further understand human genetics and hereditary disease.
- Recombinant DNA technology allows DNA from one organism to be cut and combined with DNA from another, and is used to produce medicines like human insulin in bacteria.
- Understanding an individual's genetic makeup through projects like the Human Genome Project could help develop personalized medicines tailored to each person's genetics.
- Nutrigenomics studies how different foods may affect gene expression and disease risk depending on a person's genetics. Understanding these interactions could help prevent chronic diseases.
Processing Amplicon Sequence Data for the Analysis of Microbial CommunitiesMartin Hartmann
This document provides an overview of next-generation sequencing (NGS) technologies and their usefulness for analyzing microorganisms associated with plants. It discusses how NGS methods allow addressing previously impossible questions about the composition, function, and interactions of microbial communities in environments like the rhizosphere and phyllosphere. While powerful, NGS platforms have limitations that can introduce errors or biases, but methods exist to overcome these issues. The review highlights applications of NGS in metagenomic studies of plant-associated microbiomes and how these new techniques are transforming the field.
Please enjoy the latest issue of our weekly Newsletter. Disfruten la última edición de nuestro Boletin semanal. Desfrute da mais recente edição da nossa Newsletter semanal.
Modern biotechnology Dr Nataporn Chanvarasuthcosti2014
The OECD predicts that by 2030 the bioeconomy will involve:
1) Advanced knowledge of genes and complex cell processes
2) Renewable biomass
3) Integration of biotechnology applications across sectors
Emerging technologies discussed include genome sequencing, genetic engineering, synthetic biology, additive manufacturing, and their applications in biomedicine, agriculture, renewable chemicals and biomaterials.
This document provides information on CTech Labs Pvt Ltd, an innovation and product development company. It outlines CTech's mission to partner with research institutions and inventors to develop market-worthy, customized solutions by integrating technologies with human factors. It then describes some of CTech's current and past partnerships with organizations like DRDO, Tata Steel, and IIT Bombay to develop products in areas like communications encryption, mining equipment, medical devices, and an environmental monitoring system. The document promotes CTech's services in areas like product design, business consulting, and new product development.
I spoke on "Big Data in Biology". The talk basically concentrates on how biology has affected big data and how big data has become a key player in biology. I have also covered how DNA storage can address long term archival storage.
The age of gene editing - Workshop on innovations in food and agriculture sys...OECD Environment
The workshop took place in Paris on 25-26 February 2016. Its central aim was to discuss with experts how scientific, technological, and farm practice innovation can improve productivity and sustainability in the food and agricultural sector, with a focus on international collaboration on gene editing techniques. It was introduced in the form of a presentation entitled ‘The Age of Gene editing’, produced by Steffi Friedrichs (STI), which played a pivotal role during the expert discussions.
This document discusses safe-by-design (SbD) approaches in nanotechnology from the perspective of European projects. SbD aims to minimize hazardous properties and exposure risks of nanomaterials through three key elements: safer production, safer materials and products, and safer use and end-of-life handling. The document outlines how SbD is implemented through the R&D process from product design to testing to manufacturing. It also lists several past and upcoming EU projects focused on developing SbD methods and metrics in areas like governance, data management, and risk assessment. Finally, it describes the ACEnano project's efforts to develop a tiered approach to analytical characterization techniques for improved nanomaterial risk assessment.
As with all materials, if you work with nanoparticles a few minutes of thought about safety will help you avoid problems later. Dr. Dominick Fazarro of the University of Texas at Tyler discusses nanoparticle safety. This talk provides a reasonable discussion of the potential hazards of nanoparticles and steps that can be taken to reduce these hazards.
This talk is useful for those who work with nanoparticles or manage a facility that handles nanoparticles.
20 years of evolution in data production in health and life sciencesslecrom
I share feedbacks as a genomics core facility scientific head and as a facilities manager over the last 20 years. I go trough evolution in the high throughput sequencing field and discuss about data storage and sharing.
KSPE_Medical_Apps_July_20_2016_Busan Print VerGuy J. Ofek
The document discusses the history and applications of additive manufacturing (AM) in biomedical applications. It notes that while X-rays allowed visualization of bones in 1895, AM for biomedical prototyping only became possible about 20 years ago. Applications discussed include surgical planning models from patient scans, customized hearing aids and dental devices, medical implants and tools, and novel uses such as low-cost prosthetics and a full skull transplant. The document provides examples of how AM has helped reduce surgery time and improve outcomes for complex cases.
A huge revolution has taken place in the area of Genomic science. Sequencing of millions of DNA strands in parallel and also getting a higher throughput reduces the need to implement fragment cloning methods, where extra copies of genes are produced. The methodology of sequencing a large number of DNA strands in parallel is known as Next Generation Sequencing technique. An overview of how different sequencing methods work is described. Selection of two sequencing methods, Sanger Sequencing method and Next generation sequencing method and analysis of the parameters used in both these techniques. A Comparative study of these two methods is carried out accordingly. An overview of when to use Sanger sequencing and when to use Next generation sequencing is described. Increase in the amount of genomic data has given rise to challenges like sharing, integrating and analyzing the genetic data. Therefore, application of one of the big data techniques known as Map Reduce model is used to sequence the genetic data. A flow chart of how genetic is processed using MapReduce model is also present. Next Generation Sequencing for analysis of huge amount of genetic data is very useful but it has few limitations such as scaling and efficiency. Fortunately recent researches have proven that these demerits of Next Generation Sequencing can be easily overcome by implementing big data methodologies. Chinmayee C | Amrita Nischal | C R Manjunath | Soumya K N"Next Generation Sequencing in Big Data" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-2 | Issue-4 , June 2018, URL: http://www.ijtsrd.com/papers/ijtsrd12975.pdf http://www.ijtsrd.com/computer-science/bioinformatics/12975/next-generation-sequencing-in-big-data/chinmayee-c
New tech trends 2016 - How new tech is impacting society around the worldMinter Dial
This presentation is derived from the Netexplo 2016 Trends Reports. The Netexplo Observatory, based out of Paris, hosts an annual Forum and, via a team of experts and sociologists, analyses the usages of new tech via 1000s of initiatives that have been pre-qualified by its network of new tech trend spotters.
This document discusses the experiences of an Indonesian company in developing and commercializing ECVT and ECCT technologies for cancer diagnosis and therapy. It provides an overview of the company's milestones in developing electrical capacitance volume tomography (ECVT) and electro-capacitive cancer therapy (ECCT) technologies. Key applications of ECVT discussed include industrial process imaging, brain imaging, and breast cancer scanning. ECCT is presented as a non-contact cancer therapy approach. Comparisons of ECVT and other imaging modalities for various applications are also provided.
The Future of Life Sciences 2013 for Max Planck InstituteMelanie Swan
This document provides an overview of Melanie Swan's presentation on the future of life sciences. It introduces Melanie Swan and her background. The presentation's agenda includes discussing opportunities in areas like synthetic biology, regenerative medicine, 3D printing, genomics, and quantified self-tracking. Specific opportunities highlighted include using synthetic biology for applications like biofuels, using regenerative medicine and 3D printing for organ regeneration and customized objects, and integrating diverse health data streams for personalized analysis. Risks of these technologies are also acknowledged.
The document discusses predictions for IT spending in Western Europe in 2011, with total spending expected to reach 12.24 billion dollars. Spain is predicted to spend 523 million dollars (around 390 million euros depending on exchange rate), while the UK, France, Germany, Italy, and Netherlands are each predicted to spend over 500 million dollars. The document also outlines 10 ways that information technology and healthcare are expected to evolve in 2011 and beyond, such as increased use of mobile health, electronic prescribing, clinical decision support systems, and new architectures to handle growing clinical data.
This document provides an introduction to product management. It defines a product as something sold by an enterprise to customers. Product development is the set of activities from identifying a market opportunity to producing, selling, and delivering the product. Key characteristics of successful product development include quality, cost, development time, and capability. A product development team typically includes representatives from marketing, design, manufacturing, and other functions. The document discusses trends in future products and challenges in balancing quality, value, time, and cost for new products. It also categorizes different types of new products that companies develop.
De cómo hemos pasado los científicos de escribir con buena letra y dibujar como un artista, a servirnos de la fotografía y los ordenadores para suplir nuestras deficiencias. Breve introducción de cómo hemos llegado a los superordenadores y los ordenadores personales, así como lo que hemos descubierto gracias a ellos.
Tenemos un genoma muy grande, pero no es el más grande. Pero solo una pequeña parte son genes, mientras que lo demás son fósiles, no basura. Cómo hacemos tantas cosas con tan pocos genes y cómo hemos logrado saberlo.
More Related Content
Similar to ¿Ciencia ficción o medicina personalizada? La tecnología al servicio de la salud 170604
Processing Amplicon Sequence Data for the Analysis of Microbial CommunitiesMartin Hartmann
This document provides an overview of next-generation sequencing (NGS) technologies and their usefulness for analyzing microorganisms associated with plants. It discusses how NGS methods allow addressing previously impossible questions about the composition, function, and interactions of microbial communities in environments like the rhizosphere and phyllosphere. While powerful, NGS platforms have limitations that can introduce errors or biases, but methods exist to overcome these issues. The review highlights applications of NGS in metagenomic studies of plant-associated microbiomes and how these new techniques are transforming the field.
Please enjoy the latest issue of our weekly Newsletter. Disfruten la última edición de nuestro Boletin semanal. Desfrute da mais recente edição da nossa Newsletter semanal.
Modern biotechnology Dr Nataporn Chanvarasuthcosti2014
The OECD predicts that by 2030 the bioeconomy will involve:
1) Advanced knowledge of genes and complex cell processes
2) Renewable biomass
3) Integration of biotechnology applications across sectors
Emerging technologies discussed include genome sequencing, genetic engineering, synthetic biology, additive manufacturing, and their applications in biomedicine, agriculture, renewable chemicals and biomaterials.
This document provides information on CTech Labs Pvt Ltd, an innovation and product development company. It outlines CTech's mission to partner with research institutions and inventors to develop market-worthy, customized solutions by integrating technologies with human factors. It then describes some of CTech's current and past partnerships with organizations like DRDO, Tata Steel, and IIT Bombay to develop products in areas like communications encryption, mining equipment, medical devices, and an environmental monitoring system. The document promotes CTech's services in areas like product design, business consulting, and new product development.
I spoke on "Big Data in Biology". The talk basically concentrates on how biology has affected big data and how big data has become a key player in biology. I have also covered how DNA storage can address long term archival storage.
The age of gene editing - Workshop on innovations in food and agriculture sys...OECD Environment
The workshop took place in Paris on 25-26 February 2016. Its central aim was to discuss with experts how scientific, technological, and farm practice innovation can improve productivity and sustainability in the food and agricultural sector, with a focus on international collaboration on gene editing techniques. It was introduced in the form of a presentation entitled ‘The Age of Gene editing’, produced by Steffi Friedrichs (STI), which played a pivotal role during the expert discussions.
This document discusses safe-by-design (SbD) approaches in nanotechnology from the perspective of European projects. SbD aims to minimize hazardous properties and exposure risks of nanomaterials through three key elements: safer production, safer materials and products, and safer use and end-of-life handling. The document outlines how SbD is implemented through the R&D process from product design to testing to manufacturing. It also lists several past and upcoming EU projects focused on developing SbD methods and metrics in areas like governance, data management, and risk assessment. Finally, it describes the ACEnano project's efforts to develop a tiered approach to analytical characterization techniques for improved nanomaterial risk assessment.
As with all materials, if you work with nanoparticles a few minutes of thought about safety will help you avoid problems later. Dr. Dominick Fazarro of the University of Texas at Tyler discusses nanoparticle safety. This talk provides a reasonable discussion of the potential hazards of nanoparticles and steps that can be taken to reduce these hazards.
This talk is useful for those who work with nanoparticles or manage a facility that handles nanoparticles.
20 years of evolution in data production in health and life sciencesslecrom
I share feedbacks as a genomics core facility scientific head and as a facilities manager over the last 20 years. I go trough evolution in the high throughput sequencing field and discuss about data storage and sharing.
KSPE_Medical_Apps_July_20_2016_Busan Print VerGuy J. Ofek
The document discusses the history and applications of additive manufacturing (AM) in biomedical applications. It notes that while X-rays allowed visualization of bones in 1895, AM for biomedical prototyping only became possible about 20 years ago. Applications discussed include surgical planning models from patient scans, customized hearing aids and dental devices, medical implants and tools, and novel uses such as low-cost prosthetics and a full skull transplant. The document provides examples of how AM has helped reduce surgery time and improve outcomes for complex cases.
A huge revolution has taken place in the area of Genomic science. Sequencing of millions of DNA strands in parallel and also getting a higher throughput reduces the need to implement fragment cloning methods, where extra copies of genes are produced. The methodology of sequencing a large number of DNA strands in parallel is known as Next Generation Sequencing technique. An overview of how different sequencing methods work is described. Selection of two sequencing methods, Sanger Sequencing method and Next generation sequencing method and analysis of the parameters used in both these techniques. A Comparative study of these two methods is carried out accordingly. An overview of when to use Sanger sequencing and when to use Next generation sequencing is described. Increase in the amount of genomic data has given rise to challenges like sharing, integrating and analyzing the genetic data. Therefore, application of one of the big data techniques known as Map Reduce model is used to sequence the genetic data. A flow chart of how genetic is processed using MapReduce model is also present. Next Generation Sequencing for analysis of huge amount of genetic data is very useful but it has few limitations such as scaling and efficiency. Fortunately recent researches have proven that these demerits of Next Generation Sequencing can be easily overcome by implementing big data methodologies. Chinmayee C | Amrita Nischal | C R Manjunath | Soumya K N"Next Generation Sequencing in Big Data" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-2 | Issue-4 , June 2018, URL: http://www.ijtsrd.com/papers/ijtsrd12975.pdf http://www.ijtsrd.com/computer-science/bioinformatics/12975/next-generation-sequencing-in-big-data/chinmayee-c
New tech trends 2016 - How new tech is impacting society around the worldMinter Dial
This presentation is derived from the Netexplo 2016 Trends Reports. The Netexplo Observatory, based out of Paris, hosts an annual Forum and, via a team of experts and sociologists, analyses the usages of new tech via 1000s of initiatives that have been pre-qualified by its network of new tech trend spotters.
This document discusses the experiences of an Indonesian company in developing and commercializing ECVT and ECCT technologies for cancer diagnosis and therapy. It provides an overview of the company's milestones in developing electrical capacitance volume tomography (ECVT) and electro-capacitive cancer therapy (ECCT) technologies. Key applications of ECVT discussed include industrial process imaging, brain imaging, and breast cancer scanning. ECCT is presented as a non-contact cancer therapy approach. Comparisons of ECVT and other imaging modalities for various applications are also provided.
The Future of Life Sciences 2013 for Max Planck InstituteMelanie Swan
This document provides an overview of Melanie Swan's presentation on the future of life sciences. It introduces Melanie Swan and her background. The presentation's agenda includes discussing opportunities in areas like synthetic biology, regenerative medicine, 3D printing, genomics, and quantified self-tracking. Specific opportunities highlighted include using synthetic biology for applications like biofuels, using regenerative medicine and 3D printing for organ regeneration and customized objects, and integrating diverse health data streams for personalized analysis. Risks of these technologies are also acknowledged.
The document discusses predictions for IT spending in Western Europe in 2011, with total spending expected to reach 12.24 billion dollars. Spain is predicted to spend 523 million dollars (around 390 million euros depending on exchange rate), while the UK, France, Germany, Italy, and Netherlands are each predicted to spend over 500 million dollars. The document also outlines 10 ways that information technology and healthcare are expected to evolve in 2011 and beyond, such as increased use of mobile health, electronic prescribing, clinical decision support systems, and new architectures to handle growing clinical data.
This document provides an introduction to product management. It defines a product as something sold by an enterprise to customers. Product development is the set of activities from identifying a market opportunity to producing, selling, and delivering the product. Key characteristics of successful product development include quality, cost, development time, and capability. A product development team typically includes representatives from marketing, design, manufacturing, and other functions. The document discusses trends in future products and challenges in balancing quality, value, time, and cost for new products. It also categorizes different types of new products that companies develop.
Similar to ¿Ciencia ficción o medicina personalizada? La tecnología al servicio de la salud 170604 (20)
De cómo hemos pasado los científicos de escribir con buena letra y dibujar como un artista, a servirnos de la fotografía y los ordenadores para suplir nuestras deficiencias. Breve introducción de cómo hemos llegado a los superordenadores y los ordenadores personales, así como lo que hemos descubierto gracias a ellos.
Tenemos un genoma muy grande, pero no es el más grande. Pero solo una pequeña parte son genes, mientras que lo demás son fósiles, no basura. Cómo hacemos tantas cosas con tan pocos genes y cómo hemos logrado saberlo.
El documento describe cómo la bioinformática ha contribuido a comprender la pandemia de COVID-19 desde el inicio, realizando análisis filogenéticos para determinar el origen del virus, mapeando las variantes genéticas y predictores de infectividad, y acelerando el desarrollo de vacunas y fármacos mediante la identificación de epítopos y vías afectadas. También se propone una estrategia integral bioinformática para mejorar el diagnóstico, pronóstico y tratamiento de COVID-19 y neumonía utilizando modelos de
Redacta, corrige y traduce textos científicos sin morir en el intentoM. Gonzalo Claros
Breve repaso a algunas normas de escritura científica, trampas típicas y malas costumbres. Trucos para adquirir las buenas prácticas que evitarán que se note que el texto está influido por el inglés. Hay fuentes de consulta fiables más allá de la viña de Google
El documento habla sobre la creación de nuevos términos en la ciencia. Explica que los neologismos científicos se forman a través de la acronimia, la composición de raíces griegas y latinas, y los préstamos de otras lenguas. También discute si siempre son necesarios los nuevos términos o si se pueden reemplazar por palabras ya existentes en español.
180425 Bioinformatic workflows to discover transposon/gene biomarkers in cancerM. Gonzalo Claros
The document describes a workflow called NearTrans that identifies differentially expressed transposable elements (TEs) in prostate cancer. NearTrans analyzes RNA-seq data from normal and tumor samples to detect 5 TEs, including L1PA3, L1PA4, and L1PA7, that are upregulated in prostate cancer. It also examines the closest gene to each differentially expressed TE and finds some correlations between TE and gene expression, such as for HERV17-int and the nearby ACSM1 gene.
Cómo traducir y redactar textos científicos en españolM. Gonzalo Claros
El documento presenta las reglas y normas que deben seguirse para traducir y redactar textos científicos en español. Explica las normas del Sistema Internacional, las normas ISO, el uso correcto de símbolos, unidades, notación científica, reglas ortotipográficas, y la traducción apropiada de términos y letras griegas. El objetivo es mejorar la calidad de la traducción y redacción científicas en español y evitar errores.
Cómo redactar y traducir textos científicos en español: Reglas, ideas y consejos para hacerlo bien. Se trata de una guía para traducir textos científicos, desde el Sistema Internacional hasta los compuestos químicos, pasando por el estilo científico
Traducir compuestos químicos, sustancias farmacéuticas, enzimas y anticuerpos sin saber ni química ni bioquímica. Impartida en las Jornadas de Traducción Científico-Médica de Málaga (1-3/VI/17)
This document discusses bioinformatics platforms and algorithms for studying marine organisms. It presents M. Gonzalo Claros from the University of Malaga who develops bioinformatics tools for analyzing non-model organisms. The document outlines Claros' bioinformatics strategy that combines multiple tools for assembly and annotation to obtain the best results. It also introduces some of Claros' key bioinformatics tools for preprocessing sequencing data and assembling transcripts for non-model species.
This document discusses bioinformatics in the context of the Health Engineering degree at UMA. It begins by defining bioinformatics as an attractive new scientific field at the interface of computer science, biology, and mathematics for discovering new information about diseases and the human body. It then discusses what skills a bioinformatician may need, such as programming, biology knowledge, and statistics/mathematics. Finally, it notes that bioinformatics can be applied in engineering, computing, and clinical roles to facilitate difficult tasks, improve algorithms, and discover new biological insights with computers.
The document discusses the human transcription factor network built from data in the TRANSFAC database. It finds that the network exhibits scale-free and small-world properties with a hierarchical and modular structure built around a small number of key transcription factors. Most of these key factors are associated with proliferative diseases. The network modularity reflects common structural and functional features of the transcription factors that evolved through two distinct strategies: amplification and shuffling of interacting domains, and acquisition of specific interacting regions.
Bioinformática: desde las proteínas mitocondriales a la genómicaM. Gonzalo Claros
Un resumen de mi actividad científica relacionada con la bioinformática hasta 2007. Empezando por el estudio computarizado de las amilasas para llegar a la predicción de las proteínas mitocondriales, y luego pasar a comprobar el modelo en otros eucariotas unicelulares y mis primeros pinitos en genómica con SeqTrim y Full-Lengther y el incipiente GenUMA.
Razones por las que estudiar ciencias cuando acabas el bachilleratoM. Gonzalo Claros
La ciencia busca la verdad a través del método científico y la observación, independientemente de si los descubrimientos molestan a alguien. Los descubrimientos científicos como la penicilina y las vacunas han salvado vidas. En el siglo XXI, la biotecnología, incluyendo los transgénicos, está revolucionando campos como la medicina y la agricultura. Estudiar carreras como biología, medicina y biotecnología puede conducir a una carrera emocionante ayudando a
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
PGx Analysis in VarSeq: A User’s PerspectiveGolden Helix
Since our release of the PGx capabilities in VarSeq, we’ve had a few months to gather some insights from various use cases. Some users approach PGx workflows by means of array genotyping or what seems to be a growing trend of adding the star allele calling to the existing NGS pipeline for whole genome data. Luckily, both approaches are supported with the VarSeq software platform. The genotyping method being used will also dictate what the scope of the tertiary analysis will be. For example, are your PGx reports a standalone pipeline or would your lab’s goal be to handle a dual-purpose workflow and report on PGx + Diagnostic findings.
The purpose of this webcast is to:
Discuss and demonstrate the approaches with array and NGS genotyping methods for star allele calling to prep for downstream analysis.
Following genotyping, explore alternative tertiary workflow concepts in VarSeq to handle PGx reporting.
Moreover, we will include insights users will need to consider when validating their PGx workflow for all possible star alleles and options you have for automating your PGx analysis for large number of samples. Please join us for a session dedicated to the application of star allele genotyping and subsequent PGx workflows in our VarSeq software.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
The Children are very vulnerable to get affected with respiratory disease.
In our country, the respiratory Disease conditions are consider as major cause for mortality and Morbidity in Child.
Giloy in Ayurveda - Classical Categorization and SynonymsPlanet Ayurveda
Giloy, also known as Guduchi or Amrita in classical Ayurvedic texts, is a revered herb renowned for its myriad health benefits. It is categorized as a Rasayana, meaning it has rejuvenating properties that enhance vitality and longevity. Giloy is celebrated for its ability to boost the immune system, detoxify the body, and promote overall wellness. Its anti-inflammatory, antipyretic, and antioxidant properties make it a staple in managing conditions like fever, diabetes, and stress. The versatility and efficacy of Giloy in supporting health naturally highlight its importance in Ayurveda. At Planet Ayurveda, we provide a comprehensive range of health services and 100% herbal supplements that harness the power of natural ingredients like Giloy. Our products are globally available and affordable, ensuring that everyone can benefit from the ancient wisdom of Ayurveda. If you or your loved ones are dealing with health issues, contact Planet Ayurveda at 01725214040 to book an online video consultation with our professional doctors. Let us help you achieve optimal health and wellness naturally.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Nutritional deficiency Disorder are problems in india.
It is very important to learn about Indian child's nutritional parameters as well the Disease related to alteration in their Nutrition.
Spontaneous Bacterial Peritonitis - Pathogenesis , Clinical Features & Manage...Jim Jacob Roy
In this presentation , SBP ( spontaneous bacterial peritonitis ) , which is a common complication in patients with cirrhosis and ascites is described in detail.
The reference for this presentation is Sleisenger and Fordtran's Gastrointestinal and Liver Disease Textbook ( 11th edition ).
Are you looking for a long-lasting solution to your missing tooth?
Dental implants are the most common type of method for replacing the missing tooth. Unlike dentures or bridges, implants are surgically placed in the jawbone. In layman’s terms, a dental implant is similar to the natural root of the tooth. It offers a stable foundation for the artificial tooth giving it the look, feel, and function similar to the natural tooth.
¿Ciencia ficción o medicina personalizada? La tecnología al servicio de la salud 170604
1. ¿Ciencia ficción o medicina
personalizada? La tecnología
al servicio de la salud
M. Gonzalo Claros
Profesor titular del Dpto. de Biología Molecular y Bioquímica
Plataforma Andaluza de Bioinformática
Universidad de Málaga
#TecnoMed@MGClaros AteneoConCiencia
Se añade como aportación a la imagen y a la marca UNIVERSIDAD DE MÁLAGA
un elemento secundario de identidad, la gráfica uma.es.
El objetivo es enriquecer y actualizar la imagen de la UMA. Ambas pueden ser
usadas conjuntamente en soportes digitales (nueva web, app de la UMA).
Este recurso tipográfico es creación y propiedad de la UMA y su uso ha de regirse por
las directrices que se expecifican en este manual.
La marca uma.es no sustituirá a la marca principal salvo en aquellos casos que por
natulareza del soporte no sea viable su aplicación (superficies pequeñas o de dificil
personalización).
7
D4JUN17
2. El de la UMA, devoto de Rocío y sus iniciativas
2
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://ateneomijas.org/ateneoconciencia
3. Para que esto no vuelva a ocurrir
3
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://magonia.com/2015/12/03/el-archivo-del-misterio-la-homeopatia/
http://www.elconfidencial.com/tecnologia/ciencia/2017-05-27/muere-
un-nino-de-7-anos-por-combatir-una-otitis-con-homeopatia_1389764/
http://elprofedefisica.es/libro_homeopatia.htm
En las pruebas científicas no hay
que creer, del mismo modo que
nadie cuestiona que 2 + 2 = 4
4. La ciencia ficción nos vaticina el futuro
4
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://elpais.com/elpais/2017/02/28/ciencia/1488302719_304944.html
Jules Verne
Georges Méliès
5. La medicina personalizada también tiene su ficción
5
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://www.biotekis.es/2014/10/16/medicina-personalizada-y-cine/
Mary Wollstonecraft
Godwin
2013
2009
6. Ventaja de la medicina personalizada es clara
6
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://cancersystemsbiology.net/predicting.html
Con la medicina personalizada
7. Ventaja de la medicina personalizada es clara
6
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://cancersystemsbiology.net/predicting.html
Con la medicina personalizada
8. ¿Medicina personalizada o privacidad?
7
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Insuficiente para la medicina personalizada
Insuficiente para proteger la privacidad
Variantes para medicina personalizada
Privacidad
9. La percepción del riesgo nos hace tomar decisiones erradas
8
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Antenas de móviles
Centrales eléctricas
Cables de alta tensión
10. El genoma humano: 1.er paso a la medicina personalizada
9
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://unlockinglifescode.org/timeline
1996: primer
genoma eucariota
(la levadura)
1997:
GATTACA
11. Ficción biotecnológica: GATTACA (1997)
10
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
¿Qué significa
GATTACA?
http://www.smithsonianmag.com/science-nature/nasa-picks-best-amp-
worst-sci-fi-movies-what-are-yours-41527422
Una de las obras
de ciencia-
ficción con una
base científica
más sólida de la
historia del cine
12. El ADN está hecho de G, A, T y C (GATTACA)
11
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
GenInicio
Guanina
Adenina
Timina
Citosina
13. Lo más «ficticio» de
12
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Hoy la boca es
fuente más simple
de ADN Identificación casi instantánea por el ADN
14. Las series de televisión han aprendido
13
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
15. Lo más llamativo de
14
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Hoy la boca es
fuente más simple
de ADN Identificación casi instantánea por el ADN
16. Los biochips parecían el futuro en 1997
15
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Variantes
genéticas
Análisis
forenses
Epidemiología
Citogenética
Investigación Diagnóstico
Medicina personalizada
Identificación
Permitían analizar miles de genes a la vez
18. Enorme salto de rendimiento
17
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://omicsomics.blogspot.com.es/2017/01/sequencing-technology-outlook-january.html
El
rendimiento
ha pasado a
ser 108
veces mayor
Pirosecuenciación
19. Más barato. Además, más rápido
18
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://www.genome.gov/sequencingcostsdata/
Ya podemos secuenciar un genoma humano por <1300 €
Proyecto
del genoma
humano
Pirosecuenciación
(primer método de NGS)
GA-I de Solexa
(luego Illumina) HiSeq X Ten
https://www.genome.gov/sequencingcosts/
2018:
100 €
5 días
20. ¡¡ ¿100 € un genoma? !!
19
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://scopeblog.stanford.edu/2014/01/30/coming-soon-a-genome-
test-that-costs-less-than-a-new-pair-of-shoes/
21. ¡¡ ¿100 € un genoma? !!
19
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://scopeblog.stanford.edu/2014/01/30/coming-soon-a-genome-
test-that-costs-less-than-a-new-pair-of-shoes/
¿Te plantea problemas éticos cuando estás
dando permiso a Google, Facebook o Twitter a
investigar tu vida gratis?
22. Los de Illumina tienen la «culpa»
20
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Cada HiSeq
X Ten genera
18 TB por
reacción
Una sola máquina de estas
genera 5 TB por reacción
23. Para hacernos una idea
21
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://bitesizebio.com/8378/how-much-information-is-stored-in-the-human-genome/
El genoma de una
persona equivale a
1 500 millones de
caracteres de texto
24. Para hacernos una idea
21
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://bitesizebio.com/8378/how-much-information-is-stored-in-the-human-genome/
El genoma de una
persona equivale a
1 500 millones de
caracteres de texto
Este almacenamiento
también está obsoleto
25. Acumulamos datos a mansalva
22
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://doi.org/10.1371/journal.pbio.1002195
1-17 PB/año
1-17 × 103 TB/año
1-2 TB
1-2 × 103 GB
1-2 EB/año
1-2 × 106 TB/año
1 EB/año
106 TB/año
2-40 EB/año
2-40 × 106 TB/año
55-90 €
26. Hay «bichitos» con más ADN y más genes
23
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Protistas
Plantas
Anfibios
Peces
Insectos Mamíferos
El tamaño de
nuestro genoma
¡No somos los
amos de la Tierra!
27. ¿Quienes son más «amos» que nosotros?
24
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://s-media-cache-ak0.pinimg.com/originals/ea/
ca/e0/eacae0476d503177b2a54f1db8d44d90.jpg
Humano
3 200 Mpb
La gran mayoría son
borradores
28. ¿Quienes son más «amos» que nosotros?
24
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://s-media-cache-ak0.pinimg.com/originals/ea/
ca/e0/eacae0476d503177b2a54f1db8d44d90.jpg
HumanoPino
22 180 Mpb
Abeto
noruego
20 000 Mpb
3 200 Mpb
La gran mayoría son
borradores
~7×
Paris
japonica
150 000 Mpb
45×
Ameba
670 000 Mpb
210×
29. ¿Usaremos ADN en lugar de discos duros?
25
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://revistageneticamedica.com/2017/04/19/adn-almacenamiento-datos-digitales/
Researchers Store Computer Operating System and Short Movie on DNA
New Coding Strategy Maximizes Data Storage Capacity of DNA Molecules
New York, NY - March 2, 2017 -- Humanity may soon generate more data than
hard drives or magnetic tape can handle, a problem that has scientists turning to
nature’s age-old solution for information-storage — DNA.
In a new study in Science, a pair of researchers at Columbia University and the
New York Genome Center (NYGC) show that an algorithm designed for streaming
video on a cellphone can unlock DNA’s nearly full storage potential by squeezing
more information into its four base nucleotides. They demonstrate that this
technology is also extremely reliable.
DNA is an ideal storage medium because it’s ultra-compact and can last hundreds
of thousands of years if kept in a cool, dry place, as demonstrated by the recent
recovery of DNA from the bones of a 430,000-year-old human ancestor found in a
cave in Spain.
“DNA won’t degrade over time like cassette tapes and CDs, and it won’t become
obsolete—if it does, we have bigger problems,” said study coauthor Yaniv Erlich,
a computer science professor at Columbia Engineering, a member of Columbia’s
Data Science Institute, and a core member of the NYGC.
Erlich and his colleague Dina Zielinski, an associate scientist at NYGC, chose six
files to encode, or write, into DNA: a full computer operating system, an 1895
French film, “Arrival of a train at La Ciotat,” a $50 Amazon gift card, a computer
virus, a Pioneer plaque and a 1948 study by information theorist Claude Shannon.
They compressed the files into a master file, and then split the data into short
Secuenciación
215 000 TB (2,15 × 108 GB)
de información
1 g de ADN
sin error
PCRparacopiar
1,6 bits por nucleótido
In practice, decoding took ~9 min with a Py-
thon script on a single CPU of a standard laptop
(movie S1). The decoder recovered the informa-
tion with 100% accuracy after observing only
69,870 oligos out of the 72,000 in our library
(fig. S10). To further test the robustness of our
strategy, we down-sampled the raw Illumina data
trieval of information consumes an aliquot of the
material. Copying the oligo library with PCR is
possible, but this procedure introduces noise and
induces oligo dropout. To further test the robust-
ness of our strategy, we created a deep copy of
the file by propagating the sample through nine
serial PCR amplifications (Fig. 2D). The first PCR
from an average of 7.8 perfect calls for each
per million reads (pcpm) to 4.5 pcpm in the
copy. In addition, the deep copy showed m
higher skewed representation with a neg
binomial overdispersion parameter (1/siz
0.76 compared to 0.15 in the master pool. De
the lower quality, the DNA Fountain dec
10ngoutof3µg
25µl
PCR #8PCR #7PCR #6PCR #5PCR #4PCR #3 PCR #9PCR #2PCR #1 10µl1µl1µl1µl1µl1µl1µl1µl1µl
Deepcopy
2.14Mbytetar.gz:
Perfect calls per million reads [pcpm]
Frequency
0 5 10 15 20 25 30
0.0000.0010.0020.0030.004
Mean = 7.8
Overdispersion: 0.15
Frequency
0 10 20 30 40 50 60
0.0000.0020.0040.006
Mean = 4.5
Overdispersion: 0.76
Perfect calls per million reads [pcpm]
Data payloadAdapter AdapterSeed RS5’- -3’
32Byte4Byte 2Byte
16nt24nt 8nt128nt 24nt
200nt0
72,000×
Masterpool
Perfect decoding
Sequencing on
MiSeq
25µl
MiSeq sequencing
Perfect decoding
All reads
Perfect
decoding
Perfect
decoding
All reads
Downsampling
to 5 million reads
PCR(10rounds)
Copying samples
Dilution #1
0.1x
Diluting samples
Masterpool
Masterpool
0.1x 0.1x 0.1x 0.1x 0.1x
Dilution #2 Dilution #3 Dilution #4 Dilution #5 Dilution #6 Dilution #
10ng 1ng 100pg 10pg 1pg 100fg 10fg
(215Tb/g) (2Pb/g) (21Pb/g) (215Pb/g) (2Eb/g) (21Eb/g) (215Eb/
Multiplexed
sequencing
Downsampling
to 750,000 reads
Fig. 2. Experimental setting and results for storing data on DNA.
(A) Input files for encoding, size, and type. The total amount of data was
2.14 Mbytes aftercompression.(B) Structure ofthe oligos.Black labels,length
in bytes; red, length in nucleotides; RS, Reed-Solomon error-correcting code.
(C) Experimental results of the master pool. (D) Experimental procedures
of deep copying of the oligo pool. (C and D) Histograms display the fre-
quency of perfect calls per million sequenced reads (pcpm). Red, mean;
to rescue a sufficient number of oligos. Taken
together, these results inspired us to seek a cod-
ing strategy that can better utilize the information
capacity of DNA storage devices while showing
higher data-retrieval reliability.
We devised a strategy for DNA storage, called
DNA Fountain, that approaches the Shannon ca-
pacity while providing robustness against data
corruption. Our strategy harnesses fountain codes
(18, 19), which have been developed for reliable
and effective unicasting of information over chan-
nels that are subject to dropouts, such as mobile
TV (20). In our design, we carefully adapted the
power of fountain codes to overcome both oligo
dropouts and the biochemical constraints of DNA
storage. Our encoder works in three steps (Fig.
1) (12): First, it preprocesses a binary file into a
series of nonoverlapping segments of a certain
length. Next, it iterates over two computational
steps: Luby transform and screening. The Luby
transform sets the basis for fountain codes. Basi-
cally, it packages data into any desired number
of short messages, called droplets, by selecting a
random subset of segments from the file using a
special distribution (fig. S7) and adding them
bitwise together under a binary field. The drop-
let contains two pieces of information: a data
payload part that holds the result of the addi-
tion procedure and a short, fixed-length seed.
This seed corresponds to the state of the random-
number generator of the transform during the
droplet creation and allows the decoder algo-
rithm to infer the identities of the segments in
the droplet. Theoretically, it is possible to re-
verse the Luby transform using a highly efficient
algorithm by collecting any subset of droplets
as long as the accumulated size of droplets is
slightly bigger than the size of the original file.
For DNA Fountain, our algorithm applies one
round of the transform in each iteration to create
a single droplet. Next, the algorithm moves to
the droplet screening stage. This stage is not
part of the original fountain code design and
allows us to completely realize the coding poten-
tial of each nucleotide. In screening, the algorithm
translates the binary droplet to a DNA sequence
by converting {00,01,10,11} to {A,C,G,T}, respec-
tively. Then, it screens the sequence for the
desired biochemical properties of GC content
and homopolymer runs. If the sequence passes
the screen, it is considered valid and added to
the oligo design file; otherwise, the algorithm
simply trashes the droplet. Since the Luby trans-
form can create any desired number of droplets,
we keep iterating over the droplet creation and
screening steps until a sufficient number of valid
oligos are generated. In practice, we recommend
5 to 10% more oligos than input segments (12).
Searching for valid oligos scales well with the
size of the input file and is economical for var-
ious oligo lengths within and beyond current
synthesis limits (12) (table S4).
We used DNA Fountain to encode a single
compressed file of 2,146,816 bytes in a DNA oligo
pool. The input data were in the form of a tarball
that packaged several files, including a complete
graphical operating system of 1.4 Mbytes, a movie,
and other files (12) (Fig. 2A and fig. S8). We split
the input tarball into 67,088 segments of 32 bytes
and iterated over the steps of DNA Fountain to
create valid oligos. Each droplet was 38 bytes
(304 bits): 4 bytes of the random-number gen-
erator seed, 32 bytes for the data payload, and
2 bytes for an RS error-correcting code, to reject
erroneous oligos in low-coverage conditions. With
this seed length, our strategy supports encoding
files of up to 500 Mbytes (12). The DNA oligos
had a length of 304/2 = 152 nucleotides (nt)
and were screened for homopolymer runs of
≤3 nt and GC content of 45 to 55%. We instructed
DNA Fountain to generate 72,000 oligos, yielding
a redundancy of 72,000/67,088 – 1 = 7%. We se-
lected this number of oligos due to the price
structure offered by the manufacturer, allowing
us to maximize the number of oligos per dollar.
Finally, we added upstream and downstream
annealing sites for Illumina adapters, making
our final oligos 200 nt long (Fig. 2B and fig. S9).
Encoding took 2.5 min on a single central pro-
cessing unit (CPU) of a standard laptop. We
achieved an information density of 1.57 bits/nt,
only 14% from the Shannon capacity of DNA
storage and 60% more than previous studies
with a similar scale of data (Table 1).
Sequencing and decoding the oligo pool fully
recovered the entire input file with zero errors
Fig. 1. DNA Fountain encoding. (Left) Three main algorithmic steps. (Right) Example with a small file of 32 bits. For simplicity, we partitioned the file into
eight segments of 4 bits each. The seeds are represented as 2-bit numbers and are presented for display purposes only. See (12) for the full details of each
algorithmic step.
RESEARCH | REPORT
onMarch2,2017http://science.sciencemag.org/Downloadedfrom
30. ¿Usaremos ADN en lugar de discos duros?
25
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://revistageneticamedica.com/2017/04/19/adn-almacenamiento-datos-digitales/
Researchers Store Computer Operating System and Short Movie on DNA
New Coding Strategy Maximizes Data Storage Capacity of DNA Molecules
New York, NY - March 2, 2017 -- Humanity may soon generate more data than
hard drives or magnetic tape can handle, a problem that has scientists turning to
nature’s age-old solution for information-storage — DNA.
In a new study in Science, a pair of researchers at Columbia University and the
New York Genome Center (NYGC) show that an algorithm designed for streaming
video on a cellphone can unlock DNA’s nearly full storage potential by squeezing
more information into its four base nucleotides. They demonstrate that this
technology is also extremely reliable.
DNA is an ideal storage medium because it’s ultra-compact and can last hundreds
of thousands of years if kept in a cool, dry place, as demonstrated by the recent
recovery of DNA from the bones of a 430,000-year-old human ancestor found in a
cave in Spain.
“DNA won’t degrade over time like cassette tapes and CDs, and it won’t become
obsolete—if it does, we have bigger problems,” said study coauthor Yaniv Erlich,
a computer science professor at Columbia Engineering, a member of Columbia’s
Data Science Institute, and a core member of the NYGC.
Erlich and his colleague Dina Zielinski, an associate scientist at NYGC, chose six
files to encode, or write, into DNA: a full computer operating system, an 1895
French film, “Arrival of a train at La Ciotat,” a $50 Amazon gift card, a computer
virus, a Pioneer plaque and a 1948 study by information theorist Claude Shannon.
They compressed the files into a master file, and then split the data into short
Secuenciación
215 000 TB (2,15 × 108 GB)
de información
1 g de ADN
sin error
PCRparacopiar
1,6 bits por nucleótido
In practice, decoding took ~9 min with a Py-
thon script on a single CPU of a standard laptop
(movie S1). The decoder recovered the informa-
tion with 100% accuracy after observing only
69,870 oligos out of the 72,000 in our library
(fig. S10). To further test the robustness of our
strategy, we down-sampled the raw Illumina data
trieval of information consumes an aliquot of the
material. Copying the oligo library with PCR is
possible, but this procedure introduces noise and
induces oligo dropout. To further test the robust-
ness of our strategy, we created a deep copy of
the file by propagating the sample through nine
serial PCR amplifications (Fig. 2D). The first PCR
from an average of 7.8 perfect calls for each
per million reads (pcpm) to 4.5 pcpm in the
copy. In addition, the deep copy showed m
higher skewed representation with a neg
binomial overdispersion parameter (1/siz
0.76 compared to 0.15 in the master pool. De
the lower quality, the DNA Fountain dec
10ngoutof3µg
25µl
PCR #8PCR #7PCR #6PCR #5PCR #4PCR #3 PCR #9PCR #2PCR #1 10µl1µl1µl1µl1µl1µl1µl1µl1µl
Deepcopy
2.14Mbytetar.gz:
Perfect calls per million reads [pcpm]
Frequency
0 5 10 15 20 25 30
0.0000.0010.0020.0030.004
Mean = 7.8
Overdispersion: 0.15
Frequency
0 10 20 30 40 50 60
0.0000.0020.0040.006
Mean = 4.5
Overdispersion: 0.76
Perfect calls per million reads [pcpm]
Data payloadAdapter AdapterSeed RS5’- -3’
32Byte4Byte 2Byte
16nt24nt 8nt128nt 24nt
200nt0
72,000×
Masterpool
Perfect decoding
Sequencing on
MiSeq
25µl
MiSeq sequencing
Perfect decoding
All reads
Perfect
decoding
Perfect
decoding
All reads
Downsampling
to 5 million reads
PCR(10rounds)
Copying samples
Dilution #1
0.1x
Diluting samples
Masterpool
Masterpool
0.1x 0.1x 0.1x 0.1x 0.1x
Dilution #2 Dilution #3 Dilution #4 Dilution #5 Dilution #6 Dilution #
10ng 1ng 100pg 10pg 1pg 100fg 10fg
(215Tb/g) (2Pb/g) (21Pb/g) (215Pb/g) (2Eb/g) (21Eb/g) (215Eb/
Multiplexed
sequencing
Downsampling
to 750,000 reads
Fig. 2. Experimental setting and results for storing data on DNA.
(A) Input files for encoding, size, and type. The total amount of data was
2.14 Mbytes aftercompression.(B) Structure ofthe oligos.Black labels,length
in bytes; red, length in nucleotides; RS, Reed-Solomon error-correcting code.
(C) Experimental results of the master pool. (D) Experimental procedures
of deep copying of the oligo pool. (C and D) Histograms display the fre-
quency of perfect calls per million sequenced reads (pcpm). Red, mean;
to rescue a sufficient number of oligos. Taken
together, these results inspired us to seek a cod-
ing strategy that can better utilize the information
capacity of DNA storage devices while showing
higher data-retrieval reliability.
We devised a strategy for DNA storage, called
DNA Fountain, that approaches the Shannon ca-
pacity while providing robustness against data
corruption. Our strategy harnesses fountain codes
(18, 19), which have been developed for reliable
and effective unicasting of information over chan-
nels that are subject to dropouts, such as mobile
TV (20). In our design, we carefully adapted the
power of fountain codes to overcome both oligo
dropouts and the biochemical constraints of DNA
storage. Our encoder works in three steps (Fig.
1) (12): First, it preprocesses a binary file into a
series of nonoverlapping segments of a certain
length. Next, it iterates over two computational
steps: Luby transform and screening. The Luby
transform sets the basis for fountain codes. Basi-
cally, it packages data into any desired number
of short messages, called droplets, by selecting a
random subset of segments from the file using a
special distribution (fig. S7) and adding them
bitwise together under a binary field. The drop-
let contains two pieces of information: a data
payload part that holds the result of the addi-
tion procedure and a short, fixed-length seed.
This seed corresponds to the state of the random-
number generator of the transform during the
droplet creation and allows the decoder algo-
rithm to infer the identities of the segments in
the droplet. Theoretically, it is possible to re-
verse the Luby transform using a highly efficient
algorithm by collecting any subset of droplets
as long as the accumulated size of droplets is
slightly bigger than the size of the original file.
For DNA Fountain, our algorithm applies one
round of the transform in each iteration to create
a single droplet. Next, the algorithm moves to
the droplet screening stage. This stage is not
part of the original fountain code design and
allows us to completely realize the coding poten-
tial of each nucleotide. In screening, the algorithm
translates the binary droplet to a DNA sequence
by converting {00,01,10,11} to {A,C,G,T}, respec-
tively. Then, it screens the sequence for the
desired biochemical properties of GC content
and homopolymer runs. If the sequence passes
the screen, it is considered valid and added to
the oligo design file; otherwise, the algorithm
simply trashes the droplet. Since the Luby trans-
form can create any desired number of droplets,
we keep iterating over the droplet creation and
screening steps until a sufficient number of valid
oligos are generated. In practice, we recommend
5 to 10% more oligos than input segments (12).
Searching for valid oligos scales well with the
size of the input file and is economical for var-
ious oligo lengths within and beyond current
synthesis limits (12) (table S4).
We used DNA Fountain to encode a single
compressed file of 2,146,816 bytes in a DNA oligo
pool. The input data were in the form of a tarball
that packaged several files, including a complete
graphical operating system of 1.4 Mbytes, a movie,
and other files (12) (Fig. 2A and fig. S8). We split
the input tarball into 67,088 segments of 32 bytes
and iterated over the steps of DNA Fountain to
create valid oligos. Each droplet was 38 bytes
(304 bits): 4 bytes of the random-number gen-
erator seed, 32 bytes for the data payload, and
2 bytes for an RS error-correcting code, to reject
erroneous oligos in low-coverage conditions. With
this seed length, our strategy supports encoding
files of up to 500 Mbytes (12). The DNA oligos
had a length of 304/2 = 152 nucleotides (nt)
and were screened for homopolymer runs of
≤3 nt and GC content of 45 to 55%. We instructed
DNA Fountain to generate 72,000 oligos, yielding
a redundancy of 72,000/67,088 – 1 = 7%. We se-
lected this number of oligos due to the price
structure offered by the manufacturer, allowing
us to maximize the number of oligos per dollar.
Finally, we added upstream and downstream
annealing sites for Illumina adapters, making
our final oligos 200 nt long (Fig. 2B and fig. S9).
Encoding took 2.5 min on a single central pro-
cessing unit (CPU) of a standard laptop. We
achieved an information density of 1.57 bits/nt,
only 14% from the Shannon capacity of DNA
storage and 60% more than previous studies
with a similar scale of data (Table 1).
Sequencing and decoding the oligo pool fully
recovered the entire input file with zero errors
Fig. 1. DNA Fountain encoding. (Left) Three main algorithmic steps. (Right) Example with a small file of 32 bits. For simplicity, we partitioned the file into
eight segments of 4 bits each. The seeds are represented as 2-bit numbers and are presented for display purposes only. See (12) for the full details of each
algorithmic step.
RESEARCH | REPORT
onMarch2,2017http://science.sciencemag.org/Downloadedfrom
Problema: cuesta
10 000 $
Paradoja: ¿podremos guardar información
de 1,6 nucleótidos en tan solo 1 nt?
31. Explosión genómica
26
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://www.achieversdaily.com/personalized-medicine-are-we-there-yet/
3 000
millones de €
1300 €
15 años
15 días
De paso, se impulsa la medicina personalizada
Menos costes no explican
este enorme incremento
32. El proceso también es más fácil
27
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://www.genome.gov/sequencingcosts/
Human Genome Sequencing
Generating a Reference
Genome Sequence
(e.g., Human Genome Project)
Generating a Person’s
Genome Sequence
(e.g., Circa ~2016)
Genomic DNA Genomic DNA
Break genome into
large fragments and
insert into clones
Order clones
Break individual
clones into
small pieces
Generate thousands
of sequence reads
and assemble
sequence of clone
Assemble sequences
of overlapping clones
to establish
reference sequence
Break genome
into small pieces
Generate millions
of sequence reads
Align sequence reads
to established
reference sequence
Deduce starting
sequence and identify
differences from
reference sequence
Reference Sequence
Reference Sequence
....TATGCGATGCGTATTTCGTAAA....
El proyecto del genoma humano Cualquier otro humano
La referencia
33. No todo son ventajas: inseguridad
28
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Absolutamente dependiente de
los ordenadores
Hoy solo se publican borradores llenos de agujeros
Lo que nos gustaría tener
Lo que realmente tenemos
34. Un borrador es mucho mejor que nada
29
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Traslocaciones
Explica los
cambios benignos
y las
enfermedades
Polimorfismo
mononucleotídico
35. Sabemos que todos nos parecemos
30
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
36. Por eso experimentamos con animales
31
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Y extrapolamos los resultados a los humanos
37. En el genoma cada vez quedan menos secretos
32
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://book.bionumbers.org/how-many-genes-are-in-a-genome/
Los genomas contienen más
ADN superfluo que útil
38. Ya conocíamos alguna relación gen-enfermedad
33
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://es.wikipedia.org/wiki/Enfermedad_genética
Síndrome de Down
Síndrome de Huntington
Fibrosis quística
Cáncer
Hemofilia
Diabetes de tipo 1
…
39. Descubrimos más genes relacionados con enfermedades
34
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://clinicalscientist.wordpress.com/tag/human-genome-project/
Hay millones de variaciones
La mayoría de las
enfermedades son poligénicas
40. Genoterapia: más personalizado, imposible
35
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
URL
Lentiviral vector–
mediated addition of an
antisickling β-globin
gene into autologous
hematopoietic stem
cells
Anemia
falciforme
41. Genoterapia: más personalizado, imposible
35
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
URL
Lentiviral vector–
mediated addition of an
antisickling β-globin
gene into autologous
hematopoietic stem
cells
Anemia
falciforme
Este individuo sano es transgénico
42. Pero nos queda mucho por conocer
36
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://www.seminoncol.org/article/S0093-7754(13)00216-9/pdf
Adenocarcinoma
de pulmón
Carcinoma
epidermoide
43. >30% del cáncer se debe a mutaciones imprevisibles
37
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Tomasetti et al., Science 355, 1330–1334 (2017)
No lo estamos
haciendo tan mal
44. Se pueden analizar muchos genomas a la vez
38
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
URL
Sequencing thousands of single-cell genomes with combinatorial indexing
Sarah A Vitak, Kristof A Torkenczy, Jimi L Rosenkrantz, Andrew J Fields, Lena
Christiansen, Melissa H Wong, Lucia Carbone, Frank J Steemers & Andrew Adey
Nature Methods 14, 302–308 (2017) doi:10.1038/nmeth.4154
Adenocarcinoma pancreático (PDAC) en estadio III
Se analizaron más de
16.500 células normales y
tumorales
Se diferenciaron cuatro poblaciones
diferentes en el mismo tumor, cada
una con sus variantes específicas
45. La capacidad predictiva va mejorando
39
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Un número
significativo de
variantes del
paciente le
predisponen a
una
enfermedad
Sus variantes
no están
asociadas a
ninguna
enfermedad ni
al riesgo de
padecerla
46. Se han aprobado unos pocos kits predictivos
40
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://www.fda.gov/MedicalDevices/
ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm
Es terreno abonado para
los charlatanes
La mayoría, para el cáncer
48. 41
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://francis.naukas.com/2014/01/06/francis-en-rosavientos-noticias-para-manana-sabado-2/
Gen saltarín
Neuron 81, 306–313, January 22, 2014
http://dx.doi.org/10.1016/j.neuron.2013.10.053
Síndrome de Rett
Ataxia telangiectasia
Cáncer de próstata
LINE1 (L1) está relacionado
con más enfermedades
49. 41
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
http://francis.naukas.com/2014/01/06/francis-en-rosavientos-noticias-para-manana-sabado-2/
Gen saltarín
Neuron 81, 306–313, January 22, 2014
http://dx.doi.org/10.1016/j.neuron.2013.10.053
Síndrome de Rett
Ataxia telangiectasia
Cáncer de próstata
LINE1 (L1) está relacionado
con más enfermedades
Lo que te da la vida,
también te la podría quitar
50. Nuestro genoma es una bomba de relojería
42
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
¡Tenemos más
transposones
que genes!
Procura no darle al interruptor de la cuenta atrás
Genoma nuclear humano
51. Tampoco es que todo sea NUESTRO genoma
43
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://www.snpedia.com/index.php/Obesity
Variantes relacionadas
con la obesidad
Epigenética
52. Ambiente y microbiota siguen contando
44
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Microbiota: conjunto de
microorganismos que
viven en el interior de un
ser vivo normal
53. El experimento revelador
45
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
URL
Gemelo obeso
Gemelo delgado
Ratón delgado
Ratón obeso
Ratón normal
Trasplante de
microbiota
Dieta con poca grasa
y mucha fibra
Extracción de
microbiota
Ratón delgadoRatón obeso
54. La microbiota altera los tratamientos
46
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
Article
Host-Microbe Co-metabolism Dictates Cancer Drug
Efficacy in C. elegans
Graphical Abstract
Highlights
d Drug-microbe-host high-throughput screens reveal new
mechanisms for cancer drugs
d Microbes integrate nutritional and drug cues regulating
treatment efficacy in the host
d Ribonucleotide co-metabolism of cancer pro-drugs exists
between host and microbe
d Imbalanced bacterial deoxynucleotides synergize 5-FU-
induced autophagic cell death
Authors
Timothy A. Scott, Leonor M. Quintaneiro,
Povilas Norvaisas, ..., Athanasios Typas,
Nicholas D.E. Greene, Filipe Cabreiro
Correspondence
f.cabreiro@ucl.ac.uk
In Brief
A three-way high-throughput screen
involving host-microbe-drug interactions
reveals that the beneficial impact of some
drugs can be due to effects of drug-
dependent alterations by gut microbe
composition rather than direct action of
the therapeutic itself.
HOLOBIONT
C. elegans
E. coli
Microbiota
Host
Drugconversion
Cancer survival
ImprovedUnaltered
DRUG
5-FU
Ribonucleotide
metabolism
Microbiota
conversionDrDugc
dRibonucleotide
metabolism
NUTRITION
Vitamin B6/B9
UMP precursors
Scott et al., 2017, Cell 169, 442–456
April 20, 2017 ª 2017 The Author(s). Published by Elsevier Inc.
http://dx.doi.org/10.1016/j.cell.2017.03.040
Scott et al., 2017, Cell 169, 442–456
Organismo modelo
Fármaco
Las diferencias en la
población de bacterias
del intestino explicaría
que algunos
quimioterápicos no
funcionen en ciertos
pacientes
55. Estamos llenos de bacterias que tienen su propio genoma
47
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
URL
Por dentro… …y por fuera
Nature Reviews Microbiology 9, 244-253 (April 2011)
Nature 449, 811-818 (18 October 2007)
56. Estamos llenos de bacterias que tienen su propio genoma
47
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
URL
Por dentro… …y por fuera
Nature Reviews Microbiology 9, 244-253 (April 2011)
Nature 449, 811-818 (18 October 2007)
Responsables, entre otras
muchas cosas, del olor corporal
57. Lo sabemos gracias a la metagenómica
48
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://bacpathgenomics.wordpress.com/tag/science/
58. Lo sabemos gracias a la metagenómica
48
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
https://bacpathgenomics.wordpress.com/tag/science/
Debemos abandonar la idea de enfermedades
poligénicas para convencernos que, en realidad,
las enfermedades son poligenómicas
Conocemos una cantidad ridícula
de especies de microorganismos
59. Futuro: curar los genes de «algún» genoma
49
#TecnoMed@MGClaros
5. UMA.ES
5.2. Variaciones de la marca uma.es
VERSIÓN DOS TINTAS EN POSITIVO
D4JUN17
http://about.me/mgclaros/
AteneoConCiencia